Homegrown pharma major Alembic Pharmaceuticals on Tuesday announced it has acquired the balance 40% stake in Aleor Dermaceuticals Ltd from its joint-venture partner Orbicular Pharmaceutical Technologies Private Ltd. The company did not disclose the deal size. Homegrown pharma major Alembic Pharmaceuticals on Tuesday announced it has acquired the balance 40% stake in Aleor Dermaceuticals Ltd from its jointventure partner Orbicular Pharmaceutical Technologies Private Ltd. The company did not disclose the deal size. Alembic already had a majority stake in the company. Aleor Dermaceuticals has product offerings across cream, gel, ointment, shampoo, lotion, solutions, sprays, foams, microsponge and nano-particulate platform-based products and has a formulation manufacturing facility in Gujarat. The facility is a US FDA-inspected facility and sells its products in the US market. The board of Aleor has been reconstituted with Orbicular nominees resigning from the board. The board of Alembic has also approved, subject to approval from NCLT and other regulatory bodies, the merger of Aleor with Alembic. Pranav Amin, MD, Alembic, said,
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!